Related Experiment Video
Updated: Aug 23, 2025
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
Published on: May 9, 2025
Combating challenges in CAR-T cells with engineering immunology
Clement Yisai Wang1, Stephanie Po Ting Cheung1, Ryohichi Sugimura1
1School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Abstract:
Chimeric antigen receptors (CAR) T cells (CAR-T) mark a significant step towards producing safe and effective personal anticancer treatments. CAR-T strategies engineers the T cells from the patients to allow specific binding to a tumour-specific antigen. CAR-Ts are a second-wave offensive strategy to clear out remaining chemotherapy-resistant tumour cells. Though showing practical antitumor abilities in multiple haematological malignancies and solid tumour cancers, the issues of antigen escape, tumour infiltration/penetration, and toxicity side effects limit the usage of prolonged CAR-T therapies. However, engineering immunology has exploited human stem cell-based CAR-T therapies and the development of CAR-M (macrophage) therapies to combat the disadvantages of conventional CAR-T therapies. In this review, we will highlight the challenges of CAR-T therapies and combat them with engineering immunology for cancer immunotherapy.
Insights
Chimeric antigen receptor (CAR) T-cell therapies offer personalized cancer treatment but face challenges like antigen escape and toxicity. Engineering immunology, including CAR-macrophage therapies, aims to overcome these limitations for improved cancer immunotherapy.
Area of Science:
- Immunology
- Biotechnology
- Oncology
Background:
- Chimeric antigen receptor (CAR) T-cell therapy represents a personalized approach to cancer treatment.
- CAR-T cells are engineered to target tumor-specific antigens, enhancing the immune system's attack on cancer cells.
- While effective in various cancers, CAR-T therapies face limitations including antigen escape, poor tumor infiltration, and toxicity.
Purpose of the Study:
- To review the challenges associated with conventional CAR-T cell therapies.
- To explore advancements in engineering immunology, such as CAR-T and CAR-macrophage (CAR-M) therapies.
- To discuss how these engineered immunotherapies can overcome existing limitations in cancer treatment.
Main Methods:
- Review of current literature on CAR-T cell therapy and engineering immunology.
- Analysis of strategies to address antigen escape, tumor infiltration, and toxicity.
- Examination of novel approaches like stem cell-based CAR-T and CAR-M therapies.
Main Results:
- CAR-T therapies demonstrate significant antitumor activity in hematological malignancies and solid tumors.
- Antigen escape, limited tumor penetration, and side effects remain key challenges.
- Emerging strategies like CAR-M therapies show promise in overcoming conventional CAR-T limitations.
Conclusions:
- Engineering immunology offers innovative solutions to enhance CAR-T therapy efficacy.
- CAR-T and CAR-M therapies represent a promising frontier in cancer immunotherapy.
- Continued research in engineered immune cells is crucial for advancing personalized cancer treatment.
